EGF signaling promotes the lineage conversion of astrocytes into oligodendroglia

Xinyu Liu

Zhejiang University

Lesi Xie

Zhejiang University

Jiao Li

Nanning Maternal and Child Health Hospital: The Affiliated Nanning Maternal and Child Health Hospital of Guangxi Medical University

Conghui Li

Hangzhou Normal University

Kang Zheng

Hangzhou Normal University

Xiaofeng Zhao

Hangzhou Normal University

Aifen Yang

Hangzhou Normal University

Xiaofeng Xu

Hangzhou Normal University

Huaping Tao

Hangzhou Normal University

Mengsheng Qiu

Hangzhou Normal University

Junlin Yang (✉ yjl8121@hznu.edu.cn)

Hangzhou Normal University <https://orcid.org/0000-0002-3421-7166>

Research Article

Keywords: Astrocyte, Oligodendrocyte, Transdifferentiation, EGF, Erk1/2

Posted Date: July 19th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-702088/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

The conversion of astrocytes activated by nerve injuries to oligodendrocytes is not only beneficial to axonal remyelination, but also helpful for reversal of glial scar. Recent studies have shown that Sox10 transcription factor can achieve this transdifferentiation process in collaboration with some unknown factors in the pathological microenvironment. The extracellular factors underlying the cell fate switching are not known.

Methods

Astrocytes were obtained from mouse cortical dissociation culture and purified by differential adherent properties. The lineage conversion of astrocytes into oligodendrocyte lineage cells was carried out by Sox10-expressing virus infection both *in vitro* and *in vivo*, meanwhile, epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) inhibitor Gefitinib were adopted to investigate the function of EGF signaling in this fate transition process. Pharmacological inhibition analyses were performed to examine the pathway connecting the EGF with the expression of oligodendrogenic genes and cell fate transdifferentiation.

Results

EGF treatment facilitated the Sox10-induced transformation of astrocytes to O4⁺ induced oligodendrocyte precursor cells (iOPCs) *in vitro*. The transdifferentiation of astrocytes to iOPCs went through two distinct but interconnected processes: (1) dedifferentiation of astrocytes to astrocyte precursor cells (APCs); (2) transformation of APCs to iOPCs, EGF signaling was involved in both processes. And EGF triggered astrocytes to express oligodendrogenic genes Olig1 and Olig2 by activating extracellular signal-regulated kinase 1 and 2 (Erk1/2) pathway. In addition, we discovered that EGF can enhance astrocyte transdifferentiation in injured spinal cord tissues.

Conclusions

These findings provide strong evidence that EGF facilitates the transdifferentiation of astrocytes to oligodendroglia, and suggest that targeting the EGF-EGFR-Erk1/2 signaling axis may represent a novel therapeutic strategy for myelin repair in injured central nervous system (CNS) tissues.

Background

The central nervous system (CNS) is composed of neurons, oligodendrocytes (OLs), astrocytes and microglia, among which astrocytes are the most abundant cell type. While CNS injury leads to apoptosis

of neurons and oligodendrocytes in the injured areas, astrocytes in the lesions are activated and become proliferative again. Reactive astrocytes contribute to the formation of glial scars which hinder the regeneration of axons and myelin during regeneration process [1, 2]. Thus, an ideal strategy for injury repair is to convert these reactive astrocytes to physiologically functional neurons or oligodendrocytes, as it is not only beneficial to the repair of neural circuit and remyelination, but also helpful in reducing glial hyperplasia and reversing glial scars to normal tissues. Somatic reprogramming has opened up a new avenue for tissue repair, and many studies have succeeded in direct conversion between different cell types [3–8].

It has been recently demonstrated that astrocytes can be effectively transdifferentiated to neurons both *in vivo* or *in vitro* [9, 10]. By contrast, their transdifferentiation to oligodendrocytes appears to be inefficient [11–14]. Recently, it was shown that Sox10 overexpression was capable of inducing the transdifferentiation of astrocytes to oligodendrocyte lineage cells in demyelinating tissues, but not in cultured astrocytes [11]. However, when astrocytes infected with Sox10-expressing virus were transplanted into demyelinating CNS tissues, they transdifferentiated into oligodendrocyte lineage cells. These findings suggest that Sox10 overexpression alone is not enough to reprogram astrocytes into oligodendroglia, and other extracellular signals that may exist in the pathological microenvironment are needed to achieve the cell fate switching. Exploring such extracellular factors will not only help to reveal the molecular mechanism underlying the astrocyte-to-oligodendrocyte fate change, but also aid to identify therapeutic targets for improving the efficiency of lineage conversion.

In this study, we demonstrate that epidermal growth factor (EGF) facilitates Sox10 induction of astrocyte transdifferentiation to oligodendrocyte lineage cells both *in vitro* and *in vivo*. This effect is manifested by the upregulation of Olig1 and Olig2, and mediated by activation of mitogen-activated protein kinase (MAPK) pathway in an extracellular signal-regulated kinase 1 and 2 (Erk1/2)-dependent fashion.

Materials And Methods

Preparation and purification of mouse cortical astrocytes

Mouse cortices were isolated from postnatal day 1 mouse pups, all experimental procedures were carried out in accordance with institutional guidelines for the care and use of laboratory animals, and the protocol was approved by the Animal Ethics Committee of Hangzhou Normal University, China. Cortical tissues were diced into ~ 1 mm³ pieces, then digested with 0.05% Trypsin/EDTA (w/v) in a 37°C incubator for 5 minutes, followed by adding D/F20S medium (DMEM/F-12 supplemented with 20% v/v FBS, all from Gibco) to terminate digestion. Tissues were pipetted up and down until homogenized, and then transferred into a 15 ml centrifuge tube and centrifuged at 200 g for 5 minutes at room temperature. After removing the supernatant, D/F20S medium was added to resuspend the pellet, the suspension was transferred into flasks (one brain to one T25 flask) (Corning) and incubated with 5% CO₂ at 37°C for 72 hours. Culture medium was replaced every other day. Around the 10th day after plating, mixed glial cultures became confluent, and floating cells were removed by gently rinsing twice with 1 × PBS, before

fresh D/F20S medium was added. Culture flasks were placed in incubator to equilibrate the medium for 2 hours, followed by shaking for 15–18 h (37°C, 250 rpm) with tightened caps on an orbital shaker model 420, Orbital Size 1.0 (Thermofisher, MA). During this process, microglia and OPCs that grew on the astrocyte layer detached gradually, while astrocytes adhered to the dish firmly.

For astrocyte purification, the remaining cells were digested with 0.05% Trypsin/EDTA (w/v) and plated into uncoated petri dishes, followed by incubating in a 5% CO₂, 37°C incubator for 30 minutes. The floating cells were removed and rinsed twice with 1 × PBS. The remaining cells were cultured in D/F20S medium to confluency. The purity of astrocytes was determined by immunostaining.

Generation of lentiviral particles.

For viral production, pCDH-Sox10 and pCDH-Sox10-GFP plasmids were obtained by inserting Sox10 ORF into pCDH vectors after the CMV promoter. Plasmids were prepared as previously described [15]. Lentiviral particles were generated by transfecting 293T cells. Supernatants were collected after 48 hrs, filtered through an 0.45 µm polyvinylidene difluoride filter and concentrated overnight. The viral titer was determined as previously described [16], and stored at -80°C.

Induction of the transdifferentiation of astrocytes to oligodendroglia in vitro

Purified astrocytes were placed into a 12-well plate at a density of 2×10^4 cell/cm², and infected with the reprogramming virus on the next day. 6 hours after the viral infection, the original medium was discarded and cells were washed twice with 1 × PBS and replaced with fresh glial basal media (DMEM/F12 supplemented with 1 × N2, 1 × B27 and 1 × P/S) containing 10 ng/ml PDGF $\alpha\alpha$. Medium was replaced every other day until d15.

iOPC differentiation

The directed differentiation of iOPCs into mature oligodendrocytes was performed as previously described [17]. Briefly, iOPCs were cultured in PDL/Laminin-coated chamber slides (Millipore, CA) with glial basal media supplemented with 30 ng/ml Triiodothyronine (T3) for 3 days, then examined for MBP antigen expression by immunostaining.

Preparation of O4⁺ iOPCs by immunopanning

Immunopanned Petri dishes were prepared as previously described [18, 19]. For obtaining more O4⁺ iOPCs, we used 100 mm petri dishes for transdifferentiation culture and extended the transdifferentiation culture time to 21 days. Then cells were digested with 0.05% Trypsin/EDTA (w/v), and were subsequently seeded at 2.5×10^6 per 100 mm uncoated dish and cultured for 30 min to enable astrocytes to attach to the dishes. After the incubation, the non-adherent cells were collected, and seeded into dishes coated with the O4 antibody and incubated for 30 min at room temperature. The adherent cells were then removed by treatment with 0.05% trypsin/EDTA (w/v) and replated onto the PDL/Laminin-coated dishes in glial basal media plus 10 ng/ml PDGF $\alpha\alpha$.

DRG co-culture for myelination assays

iOPCs that are used to test myelination ability were induced with pCDH-Sox10 lentivirus that does not express GFP, so that the iOPCs obtained were all GFP negative. Dorsal root ganglion neurons (DRGs) were isolated from E15 Sprague-Dawley rat embryos as previously described [20], and cultured for neurite outgrowth as described by Dincman et al., 2012 [21]. iOPCs/DRGs co-cultures were maintained for 8–12 days in glial basal media supplemented with 30 ng/ml Triiodothyronine (T3) (Sigma), and fixed for immunostaining with anti-MBP and anti-neurofilament (axons) antibodies.

qRT-PCR

For quantitative real-time reverse transcription (qRT) PCR, cells were lysed, and RNA was isolated using RNAiso Plus (9109, Takara) according to the manufacturer's manual. Total RNA samples were subjected to complementary DNA (cDNA) generation using the cDNA Synthesis kit (6210A, Takara). Samples were then subjected to quantitative PCR analysis on a Bio-Rad CFX96 Real Time PCR System. The following primer pairs were used: 5'-TTTCTCCAACCTCCAGATCC-3' and 5'-CCGCATCTCCACAGTCTTTA-3' for GFAP; 5'-GCAGCCACCTATCTCCT CATC-3' and 5'-CGAGTAGGGTAGGATAACTTCGC-3' for Olig1; 5'-GGCGGTGG

CTTCAAGTCAT-3' and 5'-CATGGCGATGTTGAGGTCG-3' for Olig2; 5'-ACCAA

AAGCAACGGAGAAGAG-3' and 5'-GGCATTCCGAAACAGGTAAGTCA-3' for Glast; 5'-GAAGCGCATGTGCGAAAGAAGA-3' and 5'-GGCGGAGGCAGTCAATT

CTC-3' for NFIA; 5'-AGTACCCGCATCTGCACAAC-3' and 5'-ACGAAGGGTCT CTTCTCGCT-3' for Sox9. Relative mRNA level was normalized against the house keeping gene GAPDH.

Surgical procedures

All experimental procedures were carried out in accordance with institutional guidelines for the care and use of laboratory animals, and the protocol was approved by the Animal Ethics Committee of Hangzhou Normal University, China. After intraperitoneal injection of tamoxifen for 5 days, adult *hGFAP^{Cre-ER}:Rosa26-tdTomato* transgenic mice were anesthetized with Nembutal (50 mg/kg, i.p.) and received a dorsal laminectomy at the tenth thoracic vertebral level (T10) to expose the spinal cord, and then a 75 kdyn contusive SCI using the IH-0400 Impactor (Infinite Horizons). At 2 d after injury, mice were randomly assigned to four groups, which received PBS, Sox10 virus, Sox10 virus + EGF, or Sox10 virus + EGF + Gefitinib, respectively. Animals were re-anesthetized as above, and the laminectomy site was re-exposed. Virus or vehicle injections were made at the center of the lesion at depth 0.7 mm. 2 µl of Sox10 lentivirus (1×10^8 IU/µl) or vehicle was injected through a glass micropipette with an outer diameter of 50–70 µm at rate of 0.5 µl/min. And then, Alzet® Osmotic Pumps (Model 1004) were installed according to the manufacturer's manual, and PBS, EGF (10 ng/µl), or EGF (10 ng/µl) plus Gefitinib (1 µM) were continuously delivered (0.11 µl/hr) in the lesion site for 21 days.

Immunostaining

Immunochemical analysis was carried out as previously described [22]. Anti-mouse O4 IgM (50%, v/v) were produced by hybridoma culture. Anti-mouse Olig2 (1:1000), anti-mouse GFAP (1:1000), and anti-rabbit neurofilament (NF-1) (1:1000) were purchased from Millipore. Anti-rat MBP (1:500) and anti-mouse CC1 (1:500) was obtained from Abcam, and anti-rabbit PDGFR α (1:500) from Santa Cruz. Anti-mouse Nestin (1:1000) and the Alexa-488 or Alexa-594 conjugated secondary antibodies were purchased from Invitrogen. The nucleic acid dye 4',6-diamidino-2-phenylindole (DAPI) was obtained from Roche.

Western immunoblotting

Western blotting was carried out as previously described [23]. Primary antibodies were used as follows: anti-Olig2 (1:3000, AB9610, Millipore), anti-GFAP (1:1000, MAB360, Millipore), anti-Nestin (1:1000, MA1-110, Invitrogen), anti-Erk1/2 (1:5000, ab184699, Abcam), and anti-p-Erk1/2 (1:5000, ab76299, Abcam). Horseradish peroxidase (HRP)-conjugated secondary antibody (Promega) was used at 1:2500. Chemiluminescent signals were detected by autoradiography using the ECL System (Amersham, Piscataway, NJ, USA).

Statistical analysis

All quantitative data are presented as Means $\pm$ SD. Statistical significance of the difference was evaluated by Student's t-test. P-value < 0.05 was considered statistically significant.

Results

EGF promotes the transdifferentiation of astrocytes into iOPCs.

Astrocytes were obtained from mouse cortical dissociation culture by differential adherent properties, as astrocytes quickly adhered to the surface of uncoated culture dishes, while other cell types were less adherent and subsequently eluted out (Fig. 1A,B). Nearly all purified cells express GFAP ($99.7 \pm 1.4\%$), and they did not express TUJ1 (neuronal marker) and Sox10 (oligodendrocyte lineage markers) (data not shown). Like reactive astrocytes *in vivo* [24], these GFAP⁺ astrocytes are immune-positive for epidermal growth factor receptor (EGFR) (Fig. 1B), suggestive of their potential responsiveness to EGF. Astrocytes were infected with lentivirus expressing oligodendrocyte lineage-specific transcription factor Sox10, and cultured in a serum-free glia basal media plus PDGF $\alpha\alpha$. After 15 days of culture, we failed to detect O4⁺ oligodendroglia, contrary to the earlier finding that overexpression of Sox10 *in vivo* induced astrocytes to transdifferentiate into oligodendroglia [11]. Therefore, we suspected that the transdifferentiation may require additional factors that are present in the pathological microenvironment.

Since EGFR is highly expressed in astrocytes, EGF is an excellent candidate for the co-stimulating factor. Therefore, EGF was tested in the Sox10 viral transfection cultures. Immunostaining results revealed that a fraction of the cells ($19.3 \pm 2.8\%$) started to express O4 antigen 15 days post infection (dpi) (Fig. 1C, D). EGF treatment alone in the absence of Sox10 virus failed to induce O4⁺ oligodendroglia (Fig. 1C, D), suggesting the lineage conversion requires the collaboration between Sox10 and EGF. Consistently, addition of EGFR inhibitor Gefitinib to the culture medium abolished the transdifferentiation effect of EGF

and Sox10 treatment (Fig. 1C, D). The induced O4⁺ cells displayed typical bipolar morphology of oligodendrocyte precursor cells (OPCs) (Fig. 1C). Under T3 stimulation, they further differentiated into MBP⁺ mature oligodendrocytes (Fig. 1E) and formed myelin sheaths around the NF-1⁺ axons when co-cultured with DRG neurons (Fig. 1F). These results indicated that EGF promotes the Sox10-mediated astrocyte fate switch to iOPCs which are capable of further differentiating into myelinating OLs.

EGF promotes the dedifferentiation of astrocytes into astrocyte precursor cells (APCs)

We next examined whether Sox10-EGF-induced reprogramming of astrocytes to iOPCs is a direct transition between these two types of cells. When the transdifferentiation procedure progressed to the 5th day, the expression level of GFAP in infected astrocytes was significantly reduced (Fig. 2A, B). The majority of cells began to express Nestin (Fig. 2A, B) and several molecular markers for astrocyte precursor cells (APCs), including Glast, NFIA and Sox9 [25, 26] (Fig. 2G), suggesting that at this stage, astrocytes started to dedifferentiate and reverse to the APC stage. Consistently, OPC-specific marker O4 antigen was not detected, and these cells could not differentiate into MBP⁺ OLs when cultured in differentiation medium (data not shown). Moreover, fetal bovine serum (FBS) treatment rapidly suppressed the expression of these precursor genes, but increased the expression of more mature astrocyte marker GFAP (Fig. 2G).

In the absence of EGF, overexpression of Sox10 only induced a small percentage of cells to express Nestin (Fig. 2A, B), and the expression levels of Glast, NFIA and Sox9 were also significantly lower than those in the Sox10 + EGF group (Fig. 2G). More importantly, a significant portion of cells ($23.8 \pm 1.6\%$) in the Sox10 + EGF group expressed Olig2 at d5 (Fig. 2A, B), while only few Olig2⁺ cells emerged in the Sox10 group at this time (Fig. 2B). In addition, EGFR inhibitor Gefitinib counteracted the effect of EGF in promoting dedifferentiation of astrocytes into APCs (Fig. 2A-G). Together, these results suggest that EGF promotes the dedifferentiation of astrocytes into APCs, the first step for enhancing astrocyte transdifferentiation into oligodendrocytes.

The transition from APCs to O4⁺ iOPCs requires EGFR signaling

To investigate the function of EGF in the process of transforming APCs to iOPCs, we treated the Sox10-infected astrocytes with EGF or its inhibitor for longer time periods as outlined in Fig. 3A. The results showed that treatment with EGF on d5-d15 induced $13.9 \pm 2.8\%$ of cells to express O4 antigen, but none in the control group (Fig. 3B, C). Gefitinib completely offset the transdifferentiation effect of EGF, indicating that EGFR activation is necessary for the transformation process. To explore whether EGF treatment during the astrocyte dedifferentiation process contributes to the subsequent transformation to iOPCs, we compared the percentage of O4⁺ cells in the d5-d15 group with the d0-d15 group and the control group, and found that the percentage of O4⁺ cells in the d5-d15 group was markedly lower than

that in the d0-d15 group. Consistent with the earlier observations with Olig2 expression, few O4⁺ cells were detected in the d0-d5 group (Fig. 3B, C). These results indicate that EGF treatment on d0-d5 significantly improved the efficiency of fate conversion. One plausible explanation for this finding is that EGF treatment yielded more Nestin⁺Olig2⁺ APCs, and the APCs obtained by EGF treatment were more readily to proceed into iOPCs.

The enhancement of astrocyte transdifferentiation to iOPCs by EGFR signaling was further validated by the inhibitory effect of Gefitinib (Fig. 3B, C). This finding is consistent with the phenomenon that EGFR signaling is required for the generation of pre-OPCs during *in vivo* development [27].

EGF signaling promotes astrocyte transdifferentiation through the Erk cascade

Expression of regulatory genes for oligodendrogenesis in EGF-treated astrocytes were measured by quantitative RT-PCR. Crucial pro-oligodendrogenic genes, such as Olig1 and Olig2 were significantly upregulated in EGF-treated astrocytes compared with control cells (Fig. 4A). It was found EGF treatment significantly increased the phosphorylation of Erk1/2 (Fig. 4B, C). Activation of Erk1/2 was blocked by both EGFR inhibitor Gefitinib and Erk inhibitor U0126 (Fig. 4B, C).

We next investigated whether Erk activity mediates EGF activation of downstream regulatory genes by adding U0126 compound to the EGF-treated astrocyte cultures and then measuring the expression of Olig1 and Olig2. U0126 treatment was found to produce a significant inhibition of EGF-induction of Olig gene expression (Fig. 4A). Meanwhile, pharmacological inhibition of Erk1/2 signaling in astrocytes also resulted in a significant reduction of O4⁺ iOPCs (Fig. 4D). These observations suggest that the Erk1/2 pathway [28] is a major downstream mediator of EGF-dependent activation of astrocytic transdifferentiation process.

EGF infusion promotes the transdifferentiation *in vivo*.

To test whether EGF enhances astrocyte transdifferentiation to oligodendroglia *in vivo*, we labelled astrocytes in *hGFAP^{Cre-ER};Rosa26-tdTomato* double transgenic mice by intraperitoneal injection of tamoxifen for 5 days. Sox10-expressing virus was then injected to lesion site two days after spinal cord contusion, followed by installation of Alzet® Osmotic Pumps (ALZET) for continuous delivery of EGF, EGF + Gefitinib or PBS in the injury site. Immunohistochemical analysis was performed on spinal cord tissue and the percentage of tdTomato⁺ astrocytes that differentiated into oligodendrocyte lineage cells was quantified for three groups of mice. In line with our *in vitro* results, EGF significantly increased the percentage of tdTomato⁺CC1⁺ induced oligodendroglia (Fig. 5A, B) compared to the control tissue that overexpressed Sox10 only. EGFR inhibitor Gefitinib counteracted the synergistic effect of EGF during transdifferentiating, and reduced the number of CC1⁺ cells to a level similar to that of the control group (Fig. 5B). Thus, EGF treatment can significantly elevate the efficiency of astrocyte transdifferentiation to oligodendrocytes *in vivo* as well.

Discussion

Earlier studies demonstrated that following CNS injury, a small number of endogenous oligodendrocytes and surrounding invading Schwann cells can participate in remyelination [29, 30]. However, later studies in humans and rodents revealed that nerve impulse conduction is still blocked, indicating that spontaneous remyelination is very limited [31, 32]. The therapeutic strategy of converting activated astrocytes to induced OLs (iOLs) has several potential advantages. First, astrocytes are widely distributed throughout the CNS and could provide a rich source for oligodendrocyte reprogramming. Secondly, transdifferentiation of activated astrocytes into oligodendrocytes will help reverse glial scar tissue, thereby promoting axon regeneration and remyelination. Finally, compared with stem cell transplantation, this strategy of using activated astrocytes for *in situ* tissue repair evokes fewer immunological and ethical issues [11]. Exploring the molecular mechanisms underlying the conversion of astrocytes into oligodendrocytes will no doubt help to achieve more effective regeneration and repair. In this study, we discovered that EGF signaling greatly promotes this fate transition process both *in vitro* and *in vivo*.

EGF is an extracellular ligand that binds to EGFR on the target cell membrane and activating several signaling cascades to convert extracellular cues into appropriate cellular responses [33]. The EGFR, also known as erbB1, is a transmembrane glycoprotein belonging to the erbB family of receptor tyrosine kinases (RTK) [34]. After ligand binding, EGFR dimerizes with itself or with its homologs erbB-2, erbB-3, or erbB-4 and autophosphorylates on key cytoplasmic residues. Activated EGFR recruits adapter proteins which in turn activates complex downstream signaling cascades [35]. Emerging evidence indicates that EGFR signaling plays an important role in oligodendrogenesis [27, 36–41]. While EGFR knock-out appeared to reduce the density of OPCs and mature oligodendrocytes in corpus callosum [36], enhancing EGFR signaling by intraventricular infusion of EGF induced type B cells to differentiate into oligodendrocytes [38]. It was also shown that the administration of intranasal heparin-binding EGF immediately after brain injury decreases oligodendroglia death and enhances generation of new oligodendrocytes [42]. In line with these findings, we discovered that EGF predisposes glial progenitor cells (GPCs) to develop into OPCs *in vitro* [33]. More recently, “EGFR⁺ pre-OPCs” were identified in developing human cerebral cortex, which originate from outer radial glial cells (oRGs), and EGF treatment resulted in a dose-dependent increase in the numbers of Olig2⁺Nkx2.2⁺ OPCs [27]. The responsiveness of pre-OPCs to EGF suggests a tight regulation of OPC production by EGF secreted in the cortical cell niche [27]. Together, these studies suggested that EGFR signaling plays an active role in cortical oligodendrogenesis.

Our results showed that EGF promoted Sox10-induced astrocyte transdifferentiation both *in vitro* and *in vivo*, which further strengthened our understanding of the function of EGF-EGFR signaling on oligodendrogenesis. Our detailed analyses revealed that EGF signaling promotes the dedifferentiation of astrocytes into APCs first, followed by the progression of APCs to OPCs in collaboration with the OPC-specific transcription factor Sox10 (Fig. 6A). Among the Nestin⁺ cells derived from the dedifferentiation of astrocytes, some might even dedifferentiate to the stage of basal multipotent intermediate progenitor cells (bMIPCs) [43]. While this study demonstrated that EGF can induce the expression of

oligodendrogenic genes Olig1 and Olig2, we previously demonstrated that Sox10 activity can stimulate Olig2 expression in neural progenitor cells to enhance oligodendrogenesis [44]. Thus, it is possible that forced expression of Sox10 in astrocytes can promote Olig2 expression and facilitates astrocyte reprogramming to iOPCs (Fig. 6B). In spinal cord injury tissues, EGF expression was significantly increased [45], which may explain why Sox10 overexpression in the injury environment was sufficient to induce astrocytes to transdifferentiate into oligodendrocytes, but failed to do so *in vitro*. In support of this concept, the transdifferentiation of astrocytes into oligodendrocytes in injury spinal tissues can be blocked by EGFR inhibitor Gefitinib.

In addition to EGF, EGFR ligands also include heparin-binding EGF-like growth factor (HB-EGF), β -cellulin, transforming growth factor alpha (TGF- α), amphiregulin (AREG), epiregulin (EREG), epigen (EPGN), neuroregulin (NRG) and Chitinase 3-like-3 (Chi3l3) [34, 46]. Theoretically, these molecules are also potential promoters for the astrocyte transdifferentiation into oligodendrocytes. Exploring the expression and function of these molecules in the pathological microenvironment will further define the molecular natures of the extracellular signals that promote the *in vivo* transdifferentiation process in injured CNS tissues.

The major signaling pathways initiated by EGFR activation include: extracellular signal-regulated kinase 1 and 2 (Erk1/2) cascade, P38MAPK cascade, c-Jun N-terminal kinase (JNK) cascade, signal transducers and activators of transcription (STAT) cascade and phospholipase C-gamma (PLC γ) cascade [34]. We demonstrated that EGF stimulation in astrocytes also significantly increased the phosphorylation level of Erk1/2. Pharmacological inhibition analysis showed that the upregulation of Erk1/2 phosphorylation is necessary for upregulation of pro-oligodendrogenic genes Olig1 and Olig2 [47–49], and subsequent transdifferentiation of astrocytes to oligodendrocytes. However, we can not rule out the possibility that EGF also influences cell fate transdifferentiation through other downstream signaling cascades, such as those involved in cellular survival and proliferation [28].

Conclusion

In summary, we found that EGF synergizes with Sox10 to transdifferentiate astrocytes to oligodendrocytes both *in vitro* and *in vivo*, and it plays an important role in both the dedifferentiation of astrocytes to APCs and the transformation of APCs to oligodendroglia. This effect was accompanied by the up-regulation of oligodendrogenic genes and mediated by the activation of MAPK pathway in an Erk1/2-dependent fashion. Our results implicate EGF-EGFR-Erk1/2 as a key intrinsic pathway influencing the astrocyte-to-oligodendrocyte fate change.

Abbreviations

iOPC: induced oligodendrocyte precursor cell; Erk1/2: extracellular signal-regulated kinase 1 and 2; APC: astrocyte precursor cell; EGF: epidermal growth factor; CNS: central nervous system; OL: oligodendrocyte; MAPK: mitogen-activated protein kinase; OPC: oligodendrocyte precursor cell;

DRG:Dorsal root ganglion neuron; T3:Triiodothyronine; EGFR:epidermal growth factor receptor; FBS:fetal bovine serum; iOL:induced oligodendrocyte; RTK:receptor tyrosine kinase; GPC:glial progenitor cell; oRG:outer radial glial cell; bMIPC:basal multipotent intermediate progenitor cell; HB-EGF:heparin-binding EGF-like growth factor; TGF- α :transforming growth factor alpha; Chi3l3:Chitinase 3-like-3; JNK:c-Jun N-terminal kinase; STAT:signal transducers and activators of transcription; PLC γ :phospholipase C-gamma.

Declarations

Acknowledgements

Not applicable.

Authors' contributions

Xinyu Liu, Lesi Xie and Jiao Li performed experiments and collected the data,, Conghui Li, Kang Zheng, Xiaofeng Zhao, Aifeng Yang, Xiaofeng Xu and Huaping Tao performed experiments; Mengsheng Qiu analyzed data and revised the manuscript. Junlin Yang designed, performed experiments, collected, analyzed the data, and wrote the manuscript. All authors have given approval to the final version of the manuscript.

Funding

This work is supported by the Zhejiang Provincial Natural Science Foundation of China (LY18H090014), the Zhejiang Provincial Medical Science and Technology Foundation of China (2021KY853) and by the National Natural Science Foundation of China (81200961, 31771621).

Availability of data and materials

Not applicable.

Ethical approval and consent to participate

All experimental procedures were carried out in accordance with institutional guidelines for the care and use of laboratory animals, and the protocol was approved by the Animal Ethics Committee of Hangzhou Normal University, China.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

References

1. Robel S, Berninger B, Götz M. The stem cell potential of glia: lessons from reactive gliosis. *Nat Rev Neurosci*. 2011;12(2):88–104.
2. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. *Acta Neuropathol*. 2010;119(1):7–35.
3. Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, et al. Induction of human neuronal cells by defined transcription factors. *Nature*. 2011;476(7359):220–3.
4. Yang N, Zuchero JB, Ahlenius H, Marro S, Ng YH, Vierbuchen T, et al. Generation of oligodendroglial cells by direct lineage conversion. *Nat Biotechnol*. 2013;31(5):434–9.
5. Najm FJ, Lager AM, Zaremba A, Wyatt K, Caprariello AV, Factor DC, et al. Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. *Nat Biotechnol*. 2013;31(5):426–33.
6. Li X, Zuo X, Jing J, Ma Y, Wang J, Liu D, et al. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. *Cell Stem Cell*. 2015;17(2):195–203.
7. Treutlein B, Lee QY, Camp JG, Mall M, Koh W, Shariati SA, et al. Dissecting direct reprogramming from fibroblast to neuron using single-cell RNA-seq. *Nature*. 2016;534(7607):391–5.
8. Pesaresi M, Sebastian-Perez R, Cosma MP. Dedifferentiation, transdifferentiation and cell fusion: in vivo reprogramming strategies for regenerative medicine. *FEBS J*. 2019;286(6):1074–93.
9. Guo Z, Zhang L, Wu Z, Chen Y, Wang F, Chen G. In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. *Cell Stem Cell*. 2014;14(2):188–202.
10. Zhang L, Yin JC, Yeh H, Ma NX, Lee G, Chen XA, et al. Small Molecules Efficiently Reprogram Human Astroglial Cells into Functional Neurons. *Cell Stem Cell*. 2015;17(6):735–47.
11. Khanghahi AM, Satarian L, Deng W, Baharvand H, Javan M. In vivo conversion of astrocytes into oligodendrocyte lineage cells with transcription factor Sox10; Promise for myelin repair in multiple sclerosis. *PLoS One*. 2018;13(9):e0203785.
12. Zare L, Baharvand H, Javan M. In vivo conversion of astrocytes to oligodendrocyte lineage cells using chemicals: targeting gliosis for myelin repair. *Regen Med*. 2018;13(7):803–19.
13. Ghasemi-Kasman M, Zare L, Baharvand H, Javan M. In vivo conversion of astrocytes to myelinating cells by miR-302/367 and valproate to enhance myelin repair. *J Tissue Eng Regen Med*. 2018;12(1):e462–72.
14. Farhangi S, Dehghan S, Totonchi M, Javan M. In vivo conversion of astrocytes to oligodendrocyte lineage cells in adult mice demyelinated brains by Sox2. *Mult Scler Relat Disord*. 2019;28:263–72.
15. Yang J, Yang Y. Plasmid size can affect the ability of *Escherichia coli* to produce high-quality plasmids. *Biotechnol Lett*. 2012;34(11):2017–22.
16. Jiang Q, Wang J, Jiang S, Wen L, Zhou H. Large-scale real-time titration of green-fluorescence-protein-marked recombinant retrovirus: comparison with standard titration method. *J First Mil Med Univ*. 2003;23(10):1101–3.

17. Cheng X, Xie B, Qi J, Zhao X, Zhang Z, Qiu M, et al. Rat astrocytes are more supportive for mouse OPC self-renewal than mouse astrocytes in culture. *Dev Neurobiol.* 2017;77(8):907–16.
18. Grinspan JB, Edell E, Carpio DF, Beesley JS, Lavy L, Pleasure D, et al. Stage-specific effects of bone morphogenetic proteins on the oligodendrocyte lineage. *J Neurobiol.* 2000;43(1):1–17.
19. Neman J, de Vellis J. A method for deriving homogenous population of oligodendrocytes from mouse embryonic stem cells. *Dev Neurobiol.* 2012;72(6):777–88.
20. Dadsetan M, Knight AM, Lu L, Windebank AJ, Yaszemski MJ. Stimulation of neurite outgrowth using positively charged hydrogels. *Biomaterials.* 2009;30(23–24):3874–81.
21. Dincman TA, Beare JE, Ohri SS, Whittemore SR. Isolation of cortical mouse oligodendrocyte precursor cells. *J Neurosci Methods.* 2012;209(1):219–26.
22. Yang J, Cheng X, Shen J, Xie B, Zhao X, Zhang Z, et al. A Novel Approach for Amplification and Purification of Mouse Oligodendrocyte Progenitor Cells. *Front Cell Neurosci.* 2016;10:203.
23. Liu X, Li C, Zheng K, Zhao X, Xu X, Yang A, et al. Chromosomal aberration arises during somatic reprogramming to pluripotent stem cells. *Cell Div.* 2020;15(1):12.
24. Liu B, Neufeld AH. Activation of epidermal growth factor receptors in astrocytes: from development to neural injury. *J Neurosci Res.* 2007;85(16):3523–9.
25. Liu Y, Han SS, Wu Y, Tuohy TM, Xue H, Cai J, et al. CD44 expression identifies astrocyte-restricted precursor cells. *Dev Biol.* 2004;276(1):31–46.
26. Domowicz MS, Henry JG, Wadlington N, Navarro A, Kraig RP, Schwartz NB. Astrocyte precursor response to embryonic brain injury. *Brain Res.* 2011;1389:35–49.
27. Huang W, Bhaduri A, Velmeshev D, Wang S, Wang L, Rottkamp CA, et al. Origins and Proliferative States of Human Oligodendrocyte Precursor Cells. *Cell.* 2020;182(3):594–608.
28. Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. *Biochim Biophys Acta.* 2011;1813(9):1619–33.
29. Gledhill RF, Harrison BM, McDonald WI. Demyelination and remyelination after acute spinal cord compression. *Exp Neurol.* 1973;38(3):472–87.
30. Itoyama Y, Webster HD, Richardson EP Jr, Trapp BD. Schwann cell remyelination of demyelinated axons in spinal cord multiple sclerosis lesions. *Ann Neurol.* 1983;14(3):339–46.
31. Alexeeva N, Broton JG, Calancie B. Latency of changes in spinal motoneuron excitability evoked by transcranial magnetic brain stimulation in spinal cord injured individuals. *Electroencephalogr Clin Neurophysiol.* 1998;109(4):297–303.
32. Nashmi R, Fehlings MG. Changes in axonal physiology and morphology after chronic compressive injury of the rat thoracic spinal cord. *Neuroscience.* 2001;104(1):235–51.
33. Yang J, Cheng X, Qi J, Xie B, Zhao X, Zheng K, et al. EGF Enhances Oligodendrogenesis from Glial Progenitor Cells. *Front Mol Neurosci.* 2017;10:106.
34. Galvez-Contreras AY, Quiñones-Hinojosa A, Gonzalez-Perez O. The role of EGFR and ErbB family related proteins in the oligodendrocyte specification in germinal niches of the adult mammalian

- brain. *Front Cell Neurosci.* 2013;7:258.
35. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene.* 2006;366(1):2–16.
 36. Aguirre A, Dupree JL, Mangin JM, Gallo V. A functional role for EGFR signaling in myelination and remyelination. *Nat Neurosci.* 2007;10(8):990–1002.
 37. Chong VZ, Webster MJ, Rothmond DA, Weickert CS. Specific developmental reductions in subventricular zone ErbB1 and ErbB4 mRNA in the human brain. *Int J Dev Neurosci.* 2008;26(7):791–803.
 38. Gonzalez-Perez O, Romero-Rodriguez R, Soriano-Navarro M, Garcia-Verdugo JM, Alvarez-Buylla A. Epidermal growth factor induces the progeny of subventricular zone type B cells to migrate and differentiate into oligodendrocytes. *Stem Cells.* 2009;27(8):2032–43.
 39. Hu Q, Zhang L, Wen J, Wang S, Li M, Feng R, et al. The EGF receptor-sox2-EGF receptor feedback loop positively regulates the self-renewal of neural precursor cells. *Stem Cells.* 2010;28(2):279–86.
 40. Fu Y, Yang M, Yu H, Wang Y, Wu X, Yong J, et al. Heterogeneity of glial progenitor cells during the neurogenesis-to-gliogenesis switch in the developing human cerebral cortex. *Cell Rep.* 2021;34(9):108788.
 41. Li X, Liu G, Yang L, Li Z, Zhang Z, Xu Z, et al. Decoding Cortical Glial Cell Development. *Neurosci Bull.* 2021;37(4):440–60.
 42. Scafidi J, Hammond TR, Scafidi S, Ritter J, Jablonska B, Roncal M, et al. Intranasal epidermal growth factor treatment rescues neonatal brain injury. *Nature.* 2014;506(7487):230–4.
 43. Huang H, Rubenstein JL, Qiu M. Cracking the Codes of Cortical Glial Progenitors: Evidence for the Common Lineage of Astrocytes and Oligodendrocytes. *Neurosci Bull.* 2021;37(4):437–9.
 44. Liu Z, Hu X, Cai J, Liu B, Peng X, Wegner M, et al. Induction of oligodendrocyte differentiation by Olig2 and Sox10: evidence for reciprocal interactions and dosage-dependent mechanisms. *Dev Biol.* 2007;302(2):683–93.
 45. Ahn YH, Bae YY, Lee G, Kang MK, Kang SK. Molecular insights of the injured lesions of rat spinal cords: Inflammation, apoptosis, and cell survival. *Biochem Biophys Res Commun.* 2006;348(2):560–70.
 46. Starossom SC, Campo Garcia J, Woelfle T, Romero-Suarez S, Olah M, Watanabe F, et al. Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. *Nat Commun.* 2019;10(1):217.
 47. Lu QR, Sun T, Zhu Z, Ma N, Garcia M, Stiles CD, et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. *Cell.* 2002;109(1):75–86.
 48. Takebayashi H, Nabeshima Y, Yoshida S, Chisaka O, Ikenaka K, Nabeshima Y. The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages. *Curr Biol.* 2002;12(13):1157–63.

49. Zhou Q, Anderson DJ. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell. 2002;109(1):61–73.

Figures

Figure 1

Sox10 and EGF act synergistically to transdifferentiate astrocytes into iOPCs A. Representative images of astrocyte purifying. (A1) Primary glial culture of mouse cortical tissue. (A2) The cells shown in A1 were passaged to uncoated dishes and cultured for 30 min, astrocytes quickly adhered to the surface of dishes, while other cells were still floating (yellow arrows). (A3) The floating cells were rinsed and

astrocytes were retained. (A4) Astrocyte morphology 24 hours after purification. B. Purified cells were immunoreactive to GFAP and EGFR antibodies. C. Representative images of the astrocyte transdifferentiation (15 dpi) in the five cultures. D. Quantifications of experiments presented in C. E. MBP+ mature OLs derived from iOPCs when cultured in the differentiation medium. F. Confocal image of myelinated axon in iOPC/DRG co-culture. Purified iOPCs matured into MBP+ OLs in the co-culture, and aligned with axons marked by neurofilament (NF-1) staining. Statistical analyses are presented as Mean $\pm$ SD, n = 3. ***P < 0.001. Scale bars, A, C, 100 μ m; B, E, 50 μ m; F, 10 μ m.

Figure 2

EGF promotes astrocyte dedifferentiation. A. Immunostaining of cells with GFAP, Nestin and Olig2 antibodies 5 days after transdifferentiation. B. Quantification of immune-positive cells in the four cultures. C. Western blotting analysis of GFAP, Nestin and Olig2 on d5 during the transdifferentiation process. D-F. Quantitative analysis of GFAP, Nestin and Olig2 proteins expression in the four cultures on d5, respectively, histograms express results in arbitrary units, taking Ctrl cells values as 100%. G. Quantitative RT-PCR analysis of the expression level of GFAP, Glast, NFIA and Sox9 in the four groups on d5 during the transdifferentiation process and Sox10 + EGF + Gefitinib group cells treated with FBS for another 3 days. Statistical analyses are presented as Mean $\pm$ SD, n = 3. **P < 0.01, ***P < 0.001. Scale bars, 75 μ m.

Figure 3

EGF promotes the switch of APCs to iOPCs. A. The schematic of EGF and Gefitinib treatments at different time points during Sox10-induced reprogramming. B. After infection with Sox10 virus, the cells were cultured in five different culture conditions for 15 days, then immunostaining was performed with O4 antibody. C. Quantification of the percentage of O4+ cells in five separate reprogramming cultures. Statistical analyses are presented as Mean $\pm$ SD, n = 3. *P < 0.05, **P < 0.01. Scale bars, 100 μ m.

Figure 4

EGF induces the expression of oligodendrogenic genes through Erk pathway A. Gene expression of Olig1 and Olig2 after 36 h of EGF and EGF + U0126 treatment. B. Western blotting analysis of p-Erk1/2 and Erk1/2 after 2 h of EGF, EGF + Gefitinib and EGF + U0126 treatment. C. Quantitative analysis of p-Erk1/2 and Erk1/2 protein expression in cultures presented in B. Histograms express results in arbitrary units, using Ctrl cell values as 100%. D. Quantification of the percentage of O4+ cells in reprogramming cultures treated with EGF or EGF + U0126. Statistical analyses are presented as Mean $\pm$ SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 5

EGF infusion promotes the transdifferentiation of astrocytes to oligodendroglia in vivo. A. Representative pictures of hGFAPCre-ER:Rosa26-tdTomato transgenic mice infused with EGF or EGF + Gefitinib during Sox10-based reprogramming and immunostained for CC1. B. Quantification of the percentage of CC1+ oligodendroglia. Statistical analyses are presented as Mean $\pm$ SD, n = 3. *P < 0.05, **P < 0.01. Scale bars, 50 μ m.

Figure 6

Proposed model of synergistic induction of transdifferentiation from astrocytes to oligodendroglia by EGF and Sox10. EGF binds to EGFR to activate the downstream Erk pathway, thereby up-regulating the expression of oligodendrogenic genes, meanwhile, forced expression of Sox10 in astrocytes also promotes Olig2 expression and facilitates astrocyte reprogramming to iOPCs via APCs.